Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01124669|
Recruitment Status : Completed
First Posted : May 17, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Genetic: DNA analysis Genetic: mutation analysis Other: laboratory biomarker analysis|
- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501.
- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen.
OUTLINE: This is a multicenter study.
DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy|
|Actual Study Start Date :||June 13, 2010|
|Actual Primary Completion Date :||July 13, 2010|
|Actual Study Completion Date :||July 13, 2010|
- Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR [ Time Frame: 1 mont ]
- Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response) [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01124669
|Principal Investigator:||Christine Chung, MD||Vanderbilt-Ingram Cancer Center|